New drug BHB810 aims to control advanced stomach cancer
Disease control
Not yet recruiting
This study tests a new drug called BHB810 in adults with advanced stomach or gastroesophageal junction cancer that has not responded to other treatments. The drug is given as an IV infusion every two weeks. The goal is to see if it is safe and can help shrink or control the cance…
Phase: PHASE1, PHASE2 • Sponsor: BigHat Biosciences, Inc. • Aim: Disease control
Last updated May 04, 2026 05:04 UTC